These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 16763917

  • 1. Substrate reduction therapy of glycosphingolipid storage disorders.
    Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M.
    J Inherit Metab Dis; 2006; 29(2-3):449-56. PubMed ID: 16763917
    [Abstract] [Full Text] [Related]

  • 2. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.
    Lachmann RH.
    Drugs Today (Barc); 2006 Jan; 42(1):29-38. PubMed ID: 16511609
    [Abstract] [Full Text] [Related]

  • 3. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
    Moyses C.
    Philos Trans R Soc Lond B Biol Sci; 2003 May 29; 358(1433):955-60. PubMed ID: 12803929
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
    Ceravolo F, Grisolia M, Sestito S, Falvo F, Moricca MT, Concolino D.
    J Med Case Rep; 2017 Jan 20; 11(1):19. PubMed ID: 28103924
    [Abstract] [Full Text] [Related]

  • 5. Substrate reduction therapy.
    Platt FM, Jeyakumar M.
    Acta Paediatr; 2008 Apr 20; 97(457):88-93. PubMed ID: 18339196
    [Abstract] [Full Text] [Related]

  • 6. Substrate reduction therapy for lysosomal storage diseases.
    Cox TM.
    Acta Paediatr Suppl; 2005 Mar 20; 94(447):69-75; discussion 57. PubMed ID: 15895716
    [Abstract] [Full Text] [Related]

  • 7. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C, Swiader L, Serratrice J.
    J Med Case Rep; 2015 Jun 23; 9():146. PubMed ID: 26100396
    [Abstract] [Full Text] [Related]

  • 8. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
    Canda E, Kose M, Kagnici M, Ucar SK, Sozmen EY, Coker M.
    Blood Cells Mol Dis; 2018 Feb 23; 68():180-184. PubMed ID: 28111116
    [No Abstract] [Full Text] [Related]

  • 9. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G, Lombardo R, Di Francesco E, Parrinello L, Di Raimondo F, Fiumara A.
    J Med Case Rep; 2016 Nov 08; 10(1):315. PubMed ID: 27821156
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases.
    Jakóbkiewicz-Banecka J, Wegrzyn A, Wegrzyn G.
    J Appl Genet; 2007 Nov 08; 48(4):383-8. PubMed ID: 17998597
    [Abstract] [Full Text] [Related]

  • 13. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease.
    Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P.
    Am J Hematol; 2005 Nov 08; 80(3):223-9. PubMed ID: 16247743
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Gaucher disease: unmet treatment needs.
    Mehta A.
    Acta Paediatr; 2008 Apr 08; 97(457):83-7. PubMed ID: 18339195
    [Abstract] [Full Text] [Related]

  • 16. Substrate reduction therapy for glycosphingolipid storage disorders.
    Lachmann RH, Platt FM.
    Expert Opin Investig Drugs; 2001 Mar 08; 10(3):455-66. PubMed ID: 11227045
    [Abstract] [Full Text] [Related]

  • 17. Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year.
    Chien YH, Lee NC, Tsai LK, Huang AC, Peng SF, Chen SJ, Hwu WL.
    J Inherit Metab Dis; 2007 Oct 08; 30(5):826. PubMed ID: 17603755
    [Abstract] [Full Text] [Related]

  • 18. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
    Amato D, Patterson MA.
    J Med Case Rep; 2018 Jan 27; 12(1):19. PubMed ID: 29373994
    [Abstract] [Full Text] [Related]

  • 19. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM, Elstein D, Hrebícek M, Zimran A.
    Clin Ther; 2007 Aug 27; 29(8):1645-54. PubMed ID: 17919546
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.